Longevity biology reached first-in-human: klotho mRNA and partial reprogramming
By the DoseRoutine Editorial Team · · · How we review content
Two of the most-hyped ideas in aging biology moved into human testing in 2026. Life Biosciences received FDA clearance for a Phase 1 trial of ER-100, a gene therapy delivering the Yamanaka factors OCT-4, SOX-2 and KLF-4 for partial epigenetic reprogramming in an eye disease, and Klothea Bio began a small Phase 1b of an alpha-klotho mRNA therapy. Both are early safety studies in tiny populations — neither is evidence that any supplement, peptide or clinic protocol extends human lifespan.
- ER-100 (Life Biosciences) is the first partial-reprogramming therapy cleared by the FDA for a human trial, targeting optic-nerve disease rather than aging as a whole.
- It delivers three of the four Yamanaka factors via AAV — deliberately omitting c-MYC, the one most associated with tumour risk.
- Klothea Bio's aKL003 is a Phase 1b of alpha-klotho mRNA in lipid nanoparticles: about 21 subjects, two injections, randomized 2:1 against saline.
- The klotho study runs at a clinic in a special economic zone in Honduras, outside the FDA/EMA pathway — a meaningful caveat for how the results should be read.
- Endpoints in both are safety, tolerability and protein expression. Neither trial can show a lifespan effect.
Partial reprogramming, in plain terms
Yamanaka factors can revert an adult cell to a stem-cell-like state. Run that process to completion and you get a pluripotent cell — useful in a dish, catastrophic in a living tissue, because cells that forget what they are become tumours. Partial reprogramming applies the factors briefly, aiming to reset age-associated epigenetic marks while the cell keeps its identity. In mice it has restored vision in damaged optic nerves.
Life Biosciences' ER-100 takes that into people with optic-nerve disease, where the eye offers a contained compartment, a measurable endpoint and a manageable risk profile. That choice tells you how early this is: nobody is dosing a healthy person systemically with reprogramming factors.
Klotho, and why the trial design matters
Alpha-klotho is a protein whose levels fall with age and correlate with kidney function, cognition and cardiovascular health; overexpressing it extends lifespan in mice. Klothea's approach is mRNA in a lipid nanoparticle — the delivery platform proven at scale by COVID vaccines — to make the body transiently produce klotho itself.
The trial is 21 subjects, two doses, randomized against saline, measuring safety and protein expression. It is being run at the GARM Clinic in Próspera, Roatán, a jurisdiction chosen by several longevity companies to move faster than conventional regulators allow. Speed is real; so is the reduced oversight, and results from that setting will face a higher bar before mainstream adoption.
What this does and does not license you to do
- It does not validate any supplement marketed as a 'klotho booster'. No oral product has been shown to raise circulating alpha-klotho meaningfully in humans.
- It does not validate peptide 'reprogramming' protocols, epitalon, or exosome infusions sold by longevity clinics. None of these are the therapies in trial.
- It does mean the mechanisms are now testable in humans, with real safety data arriving within a couple of years.
- The interventions with actual human outcome evidence are unchanged: resistance and aerobic training, sleep, blood pressure and lipid control, glucose regulation, not smoking, and treating what your labs actually show.
How to read longevity news without getting sold something
- Check the species. Most 'lifespan extension' headlines are mice, worms or cells.
- Check the endpoint. Phase 1 measures safety and drug levels — never longevity.
- Check the n. Twenty-one people cannot show efficacy for anything.
- Check the regulator. A trial outside FDA/EMA oversight is not automatically bad science, but it is a different evidentiary standard.
- Check who profits from your conclusion. Clinics quoting Phase 1 press releases while selling infusions are the pattern to distrust.
This is a summary of published research for general information. Investigational drugs are not available outside clinical trials, and research chemicals sold online are not the same products. Talk to a clinician who knows your history and labs before changing anything you take.
Frequently asked questions
Has partial reprogramming been tested in humans?
Yes, as of 2026. Life Biosciences received FDA clearance for a Phase 1 trial of ER-100, an AAV gene therapy delivering OCT-4, SOX-2 and KLF-4 to partially reprogram cells, in people with optic-nerve disease. It is a safety study, not a lifespan study.
What is the klotho trial?
Klothea Bio is running a Phase 1b randomized, double-blind, placebo-controlled study of aKL003, an alpha-klotho mRNA in lipid nanoparticles. About 21 subjects receive two injections at 0.5 mg, randomized 2:1 against saline, with safety, tolerability and protein expression as endpoints.
Can I take a supplement to increase klotho?
No supplement has been shown to raise circulating alpha-klotho to a clinically meaningful degree in humans. Observational data link higher klotho with exercise and kidney health, but that is not the same as a product that raises it.
Why omit c-MYC from the Yamanaka factors?
c-MYC is a well-known oncogene, and its inclusion is the main tumour-risk driver in reprogramming. Using only OCT-4, SOX-2 and KLF-4 keeps most of the rejuvenation effect seen in animal work while lowering that risk, which is why clinical programs use the three-factor combination.
Are longevity clinics offering these therapies now?
Some clinics sell products with similar names — exosomes, peptide 'reprogramming' protocols, klotho-branded supplements. None of them are the therapies being tested in these trials, and none have human outcome data behind them.
Keep reading
About the author
DoseRoutine Editorial Team — Maintainers of the DoseRoutine compound library and interaction rule set
The DoseRoutine Editorial Team maintains the compound library and the interaction rule set behind DoseRoutine.
We summarize published trials, regulatory documents (FDA, EMA) and company announcements into plain-English updates. Every factual claim on a post is tied to a linked source below.
Posts are written and reviewed by the editorial team, not by a licensed clinician. This is educational reference content — it never recommends an amount for you to take.
Sources & references
5 sources — primary literature, regulatory documents and company announcements, each linked to the original document. Last reviewed . How we select and review sources.
- Peer-reviewedNature Biotechnology. FDA go-ahead to test cellular rejuvenation therapy in humans. February 17, 2026. View source on nature.com
- Trial registryClinicalTrials.gov. aKLmRNA-mediated Protein Replacement Therapy (aKL003), NCT07544420. Klothea Bio Inc. View source on clinicaltrials.gov
- ReferenceLongevity.Technology. Klothea initiates longevity-focused human trial of klotho therapy. February 24, 2026. View source on longevity.technology
- Peer-reviewedLu Y, et al. Reprogramming to recover youthful epigenetic information and restore vision. Nature. 2020;588(7836):124–129. View source on pubmed.ncbi.nlm.nih.gov
- Peer-reviewedKuro-o M, et al. Mutation of the mouse klotho gene leads to a syndrome resembling aging. Nature. 1997;390(6655):45–51. View source on pubmed.ncbi.nlm.nih.gov